Cargando…

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

The utility of spatial immunobiomarker quantitation in prognostication and therapeutic prediction is actively being investigated in triple-negative breast cancer (TNBC). Here, with high-plex quantitative digital spatial profiling, we map and quantitate intraepithelial and adjacent stromal tumor immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carter, Jodi M., Chumsri, Saranya, Hinerfeld, Douglas A., Ma, Yaohua, Wang, Xue, Zahrieh, David, Hillman, David W., Tenner, Kathleen S., Kachergus, Jennifer M., Brauer, Heather Ann, Warren, Sarah E., Henderson, David, Shi, Ji, Liu, Yi, Joensuu, Heikki, Lindman, Henrik, Leon-Ferre, Roberto A., Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna R., Couch, Fergus J., Knutson, Keith L., Goetz, Matthew P., Perez, Edith A., Thompson, E. Aubrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113250/ https://www.ncbi.nlm.nih.gov/pubmed/37072398 http://dx.doi.org/10.1038/s41467-023-37806-0

Ejemplares similares

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
por: Norton, Nadine, et al.
Publicado: (2020)

PDJ amplicon in triple negative breast cancer
por: Roesler, Alexander S., et al.
Publicado: (2023)

Next generation of immune checkpoint therapy in cancer: new developments and challenges
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy
por: Sammons, Sarah, et al.
Publicado: (2022)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
por: Soyano, Aixa E., et al.
Publicado: (2018)

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
por: Chumsri, Saranya, et al.
Publicado: (2022)

Sample size planning in the design and analysis of cluster randomized trials using the symbolic two-step method
por: Zahrieh, David, et al.
Publicado: (2020)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Tumor-infiltrating lymphocytes and outcome in Merkel cell carcinoma, a virus-associated cancer
por: Sihto, Harri, et al.
Publicado: (2012)

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions
por: Bauer, Sebastian, et al.
Publicado: (2015)

The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data
por: Tang, Xiaojia, et al.
Publicado: (2014)

Quantification of Potential Inequities in Breast Cancer Incidence in New Mexico Through Bayesian Disease Mapping
por: Zahrieh, David, et al.
Publicado: (2021)

Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination
por: Robinson, Kristin A., et al.
Publicado: (2021)

Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients
por: Advani, Pooja, et al.
Publicado: (2021)

Gene Expression, Single Nucleotide Variant and Fusion Transcript Discovery in Archival Material from Breast Tumors
por: Norton, Nadine, et al.
Publicado: (2013)

Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
por: Necela, Brian M., et al.
Publicado: (2017)

Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations
por: Kalari, Krishna R., et al.
Publicado: (2012)

Asymptomatic coronavirus disease 2019 mimicking metastatic breast cancer on positron emission tomography/computed tomography imaging
por: Pai, Tanmayi S., et al.
Publicado: (2021)

Whole-Genome Sequence of the C57L/J Mouse Inbred Strain
por: Ananda, Guruprasad, et al.
Publicado: (2014)

Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer
por: Seneviratne, Danushka, et al.
Publicado: (2022)

Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays
por: Mutter, George L, et al.
Publicado: (2004)

Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study
por: Alexiev, Borislav A, et al.
Publicado: (2007)

Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
por: Barok, Mark, et al.
Publicado: (2021)

Clinical Outcomes and Prognostic Factors In Triple-Negative Invasive Lobular Carcinoma of the Breast
por: Joshi, Utsav, et al.
Publicado: (2023)

RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells
por: Brusgard, Jessica L., et al.
Publicado: (2015)

Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer
por: Gardner, Kirby P., et al.
Publicado: (2022)

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer
por: Kazi, Armina A, et al.
Publicado: (2014)

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer
por: Kalari, Krishna R., et al.
Publicado: (2013)

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
por: Bhatnagar, Bhavana, et al.
Publicado: (2014)

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
por: Tomita, Yusuke, et al.
Publicado: (2016)

CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome
por: Raghavakaimal, Ashvathi, et al.
Publicado: (2022)

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
por: An, Zesheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gskouca8t83v23v0bd1hvradc4